Pharmacogenomic implications of population admixture: Brazil as a model case

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Callegari-Jacques SM, Salzano FM. Brazilian Indian/non Indian interactions and their effects. Cienc. Cult.51(3–4),166–174 (1999).
  Google Scholar
• 2  Suarez-Kurtz G, Pena SDJ. Pharmacogenetic studies in the Brazilian population. In: Pharmacogenomics in Admixed Populations. Suarez-Kurtz G (Ed.). Landes Biosciences, Austin, TX, USA, 75–98 (2007).
  Google Scholar
• 3  Suarez-Kurtz G. Pharmacogenomic applications in the developing world: the American continent. In: Genomics Applications for the Developing World. Nelson KE, Jones-Nelson B (Eds). Springer, Heidelberg, Germany, 147–160 (2012).
  Google Scholar
• 4  Suarez-Kurtz G, Pena SDJ, Struchiner CJ, Hutz MH. Pharmacogenomic diversity among Brazilians: influence of diversity, self reported color and geographical origin. Front. Pharmacol.3,191 (2012).
  MedlineGoogle Scholar
• 5  Bastos-Rodrigues L, Pimenta JR, Pena SDJ. The genetic structure of human populations studied through short insertion–deletion polymorphisms. Ann. Hum. Genet.70(5),658–665 (2006).
  MedlineGoogle Scholar
• 6  Salzano FM, Bortolini MC. The Evolution and Genetics of Latin American Populations. Cambridge University Press, Cambridge, UK (2002).▪ Overview of population genetics in Latin America.
  Google Scholar
• 7  Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SDJ. Color and genomic ancestry in Brazilians. Proc. Natl Acad. Sci. USA100(1),177–182 (2003).
  Medline CASGoogle Scholar
• 8  Pena SDJ, Di-Pietro G, Fuchshuber-Moraes M et al. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS ONE6(2),e17063 (2011).▪▪ Analysis of the biogeographical ancestry of Brazilians, using a validated panel of ancestry-informative markers.
  Medline CASGoogle Scholar
• 9  Suarez-Kurtz G. Pharmacogenetics in the Brazilian population. Front. Pharmacol.1(118),1–10 (2010).▪▪ Overview of the population structure and pharmacogenomics of Brazilians.
  MedlineGoogle Scholar
• 10  Suarez-Kurtz G, Vargens DD, Struchiner CJ, Bastos-Rodrigues L, Pena SDJ. Self-reported skin color, genomic ancestry and the distribution of GST polymorphisms. Pharmacogenet. Genomics17(9),765–771 (2007).
  Medline CASGoogle Scholar
• 11  Suarez-Kurtz G, Perini JA, Bastos-Rodrigues L, Pena SD, Struchiner C. Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics8,1299–1306 (2007).
  CASGoogle Scholar
• 12  Estrela RC, Ribeiro FS, Carvalho RS et al. Distribution of ABCB1 polymorphisms among Brazilians: impact of population admixture. Pharmacogenomics9,267–276 (2008).
  CASGoogle Scholar
• 13  Vargens DD, Almendra L, Struchiner CJ, Suarez-Kurtz G. Distribution of the GNB3 825C>T polymorphism among Brazilians: impact of population structure. Eur. J. Clin. Pharmacol.3,253–256 (2008).
  Google Scholar
• 14  Suarez-Kurtz G, Amorim A, Damasceno A et al.VKORC1 polymorphisms in Brazilians, comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications. Pharmacogenomics11,1257–1267 (2010).▪ Original study of warfarin pharmacogenomics in Latin American populations.
  CASGoogle Scholar
• 15  Suarez-Kurtz G, Genro JP, Moraes MO et al. Global pharmacogenomics: impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. Pharmacogenomics J.12,267–276 (2012).
  Medline CASGoogle Scholar
• 16  Perini JA, Petzl-Erler ML, Tsuneto LT, Suarez-Kurtz G. VKORC1 polymorphisms in Amerindian populations of Brazil. Pharmacogenomics9,1623–1629 (2008).
  CASGoogle Scholar
• 17  Vargens DD, Damasceno A, Petzl-Erler ML, Suarez-Kurtz G. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among Amerindians, Mozambicans and Brazilians. Pharmacogenomics12,769–772 (2011).
  CASGoogle Scholar
• 18  Suarez-Kurtz G, Pena SD, Hutz MH. Application of the F(ST) statistics to explore pharmacogenomic diversity in the Brazilian population. Pharmacogenomics13,771–777 (2012).▪ Examines the extent of pharmacogenomic diversity among Brazilians and between Brazilians and HapMap populations.
  CASGoogle Scholar
• 19  Wright S. The genetic structure of populations. Ann. Eugen.15,323–3543 (1951).
  Medline CASGoogle Scholar
• 20  Wright S. Variability Within and Among Natural Populations. University of Chicago Press, IL, USA, 4 (1978).
  Google Scholar
• 21  Estrela RC, Santoro AB, Barroso PF, Tuyama M, Suarez-Kurtz G. CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects. Clin. Pharmacol. Ther.84,205–207 (2008).
  Medline CASGoogle Scholar
• 22  Kohlrausch FB, Salatino-Oliveira A, Gama CS, Lobato MI, Belmonte-de-Abreu P, Hutz MH. G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics. Pharmacogenomics9,1429–1436 (2008).
  CASGoogle Scholar
• 23  Perini JA, Struchiner CJ, Silva-Assuncao E et al. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin. Pharmacol. Ther.84,722–728 (2008).
  Medline CASGoogle Scholar
• 24  Suarez-Kurtz G, Perini JA, Silva-Assuncao E, Struchiner CJ. Relative contribution of VKORC1, CYP2C9 and INR response to warfarin stable dose. Blood113,4125–4126 (2009).
  Medline CASGoogle Scholar
• 25  Perini JA, Struchiner CJ, Silva-Assuncao E, Suarez-Kurtz G. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin. Pharmacol. Ther.87,417–420 (2010).
  Medline CASGoogle Scholar
• 26  Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther.84,326–331 (2008).
  Medline CASGoogle Scholar
• 27  International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med.360(8),753–764 (2009). Erratum in: N. Engl. J. Med.361(16),1613 (2009).
  Medline CASGoogle Scholar
• 28  Limdi NA, Wadelius M, Cavallari L et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across three racial groups. Blood115,3827–3834 (2010).
  Medline CASGoogle Scholar
• 29  Botton M, Bandinelli E, Rohde L, Amon L, Hutz M. Influence of genetic, biological and pharmacological factors on warfarin dose in a southern Brazilian population of European ancestry. Br. J. Clin. Pharmacol.72(3),442–450 (2011).
  Medline CASGoogle Scholar
• 30  Suarez-Kurtz G. Population diversity and the performance of warfarin dosing algorithms. Br. J. Clin. Pharmacol.72,451–453 (2011).
  Medline CASGoogle Scholar
• 31  Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin. Pharmacokinet.49,141–175 (2010).
  Medline CASGoogle Scholar
• 32  Tavira B, Coto E, Diaz-Corte C et al. Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clin. Chem. Lab. Med.49,825–833 (2011).
  Medline CASGoogle Scholar
• 33  Elens L, Bouamar R, Hesselink DA et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem.57,1574–1583 (2011).
  Medline CASGoogle Scholar
• 34  de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR. In vivoCYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin. Pharmacol. Ther.92,366–375 (2012).
  Medline CASGoogle Scholar
• 35  Santoro A, Felipe CR, Tedesco-Silva H et al. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics12,1293–1303 (2011).▪ First demonstration of the gene–dose effect of CYP3A5 polymorphisms on tacrolimus dose requirements in renal transplant recipients.
  CASGoogle Scholar
• 36  Santoro AB, Struchiner CJ, Felipe CR et al.CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients. Clin. Pharmacol. Ther.94(2),201–202 (2013).
  Medline CASGoogle Scholar
• 37  van Gelder T, van Schaik RH, Hesselink DA. Practicability of pharmacogenetics in transplantation medicine. Clin. Pharmacol. Ther. doi:10.1038/clpt.2013.169 (2013) (Epub ahead of print).
  Google Scholar
• 38  Johnson EG, Horne BD, Carlquist JF, Anderson JL. Genotype-based dosing algorithms for warfarin therapy: data review and recommendations. Mol. Diagn. Ther.15(5),255–264 (2011).
  Medline CASGoogle Scholar
• 39  Suarez-Kurtz G. Pharmacogenetics in admixed populations. Trends Pharmacol. Sci.26(4),196–201 (2005).
  Medline CASGoogle Scholar
• 40  Suarez-Kurtz G (Ed.). Pharmacogenomics in Admixed Populations. Landes Biosciences, Austin, TX, USA (2007).
  Google Scholar
• 101  Countries ranked by Gross Domestic Product. http://en.wikipedia.org/wiki/List_of_countries_by_GDP_(nominal)
  Google Scholar
• 102  The Human Development Index used by the United Nations Development Program to rank countries. http://en.wikipedia.org/wiki/Human_Development_Index
  Google Scholar
• 103  Home Page of the Instituto Brasileiro de Geografia e Estatística (IBGE), responsible for the Brazilian Census. www.ibge.gov.br
  Google Scholar
• 104  Brazilian Pharmacogenomics Network, Refargen. www.refargen.org.br
  Google Scholar
• 105  Refargen database of pharmacogenomic polymorphisms in Brazilians. www.refargen.org.br/rubrique.php3?id_rubrique=28
  Google Scholar
• 106  Pharmacogenomics Knowledge Base (PharmGKB): Browse Annotated PGx Genes. www.pharmgkb.org/search/browseVip.action?browseKey=annotatedGenes
  Google Scholar
• 107  International HapMap project. http://hapmap.ncbi.nlm.nih.gov
  Google Scholar